Duopharma Biotech Bhd (XKLS:7148) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:7148 Duopharma Biotech Bhd XKLS:7148
87 GF Score
Price RM1.16
GF Value RM1.50
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Duopharma Biotech Bhd  (XKLS:7148) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Duopharma Biotech Bhd Cyclically Adjusted PS Ratio Related Terms


Duopharma Biotech Bhd Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Cyclically Adjusted PS Ratio Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.24 2.70 1.93 1.75 1.62

Duopharma Biotech Bhd Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.74 1.70 1.61 1.58 1.44

XKLS:7148 vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio falls into.


XKLS:7148
87GF Score
Duopharma Biotech Bhd XKLS:7148
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Duopharma Biotech Bhd's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.244/333.9520*333.9520
=0.244

Current CPI (Jun. 2026) = 333.9520.

Duopharma Biotech Bhd Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.093 241.428 0.129
201612 0.085 241.432 0.118
201703 0.139 243.801 0.190
201706 0.135 244.955 0.184
201709 0.133 246.819 0.180
201712 0.129 246.524 0.175
201803 0.154 249.554 0.206
201806 0.142 251.989 0.188
201809 0.143 252.439 0.189
201812 0.131 251.233 0.174
201903 0.170 254.202 0.223
201906 0.165 256.143 0.215
201909 0.159 256.759 0.207
201912 0.151 256.974 0.196
202003 0.174 258.115 0.225
202006 0.157 257.797 0.203
202009 0.144 260.280 0.185
202012 0.142 260.474 0.182
202103 0.177 264.877 0.223
202106 0.165 271.696 0.203
202109 0.182 274.310 0.222
202112 0.154 278.802 0.184
202203 0.200 287.504 0.232
202206 0.192 296.311 0.216
202209 0.186 296.808 0.209
202212 0.160 296.797 0.180
202303 0.211 301.836 0.233
202306 0.175 305.109 0.192
202309 0.176 307.789 0.191
202312 0.174 306.746 0.189
202403 0.201 312.332 0.215
202406 0.227 314.175 0.241
202409 0.217 315.301 0.230
202412 0.201 315.605 0.213
202503 0.273 319.799 0.285
202506 0.231 322.561 0.239
202509 0.231 324.800 0.238
202512 0.234 324.054 0.241
202603 0.258 330.213 0.261
202606 0.244 333.952 0.244

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.16 is trading 22.7% below its estimated GF Value™ of RM1.50. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: RM1.50 vs. price of RM1.16 (22.7% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
87GF Score

Get the complete analysis for XKLS:7148

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.16
Price
RM1.50
GF Value